首页|老年特发性膜性肾病患者临床特点及初始治疗效果分析

老年特发性膜性肾病患者临床特点及初始治疗效果分析

扫码查看
目的 探讨老年特发性膜性肾病(IMN)患者的临床特点及初始治疗效果.方法 回顾性分析年龄≥60岁,肾活检证实为膜性肾病住院患者的临床特点并分析随访1年的治疗效果.结果 本研究共纳入91例老年IMN患者,男性51例(56.0%),女性40例(44.0%),年龄中位数为67岁,尿蛋白肌酐比值(uPCR)中位数为4 454.3 mg/g,尿白蛋白肌酐比值(uACR)中位数为2 258.5 mg/g,24 h尿蛋白值中位数为5 098.2 mg/24 h,24 h尿白蛋白值中位数为2 800.6 mg/24 h,估算肾小球滤过率(eGFR)平均值为(60.5±20.4)ml·min-1·1.73m-2.肾活检后1年获得缓解(包括完全缓解和部分缓解)共61例(67.0%).其中缓解组的uPCR、uACR均高于不缓解组(5 462.5比2271.1 mg/g,P<0.001;2 774.4 比 1 320.0 mg/g,P=0.001),同时缓解组的 24 h 尿蛋白值和 24 h尿白蛋白值均高于不缓解组(6 526.4 比 3 210.4 mg/g,P=0.002;3 067.7 比 2 102.4 mg/g,P=0.007),且缓解组使用免疫抑制剂治疗的比例高于不缓解组(85.2%比33.3%,P<0.001).对不同治疗方案进行两两比较,激素联合环磷酰胺、激素联合钙调神经磷酸酶抑制剂或激素联合吗替麦考酚酯3者的缓解率均高于保守治疗(88.2%比31.0%,P=0.001;80.0%比31.0%,P<0.001;100.0%比31.0%,P=0.007),而免疫抑制治疗3组两两比较缓解率差异无统计学意义(P>0.05).进一步分析发现激素联合环磷酰胺、激素联合钙调神经磷酸酶抑制剂或激素联合吗替麦考酚酯与保守治疗相比,3组的uPCR、uACR和血清胱抑素C(CysC)均高于保守治疗组,血清总蛋白和白蛋白均低于保守治疗组(P<0.05).结论 老年IMN患者多数合并症较多,对于尿蛋白水平较高的高危患者早期给予免疫抑制治疗可获得更高的初始尿蛋白缓解率.临床上需根据患者临床特点,衡量免疫抑制治疗的利弊,更好地为老年IMN患者实施个体化治疗.
Clinical features and initial outcomes in elderly patients with idiopathic membranous nephropathy
Objective The purpose of this study was to examine the clinical features and initial treatment outcomes of elderly individuals with idiopathic membranous nephropathy.Methods This study retrospectively analyzed the clinical characteristics and therapeutic effect of hospitalized patients aged 60 years or older with renal-biopsy-proven idiopathic membranous nephropathy for at least one year.Results This study enrolled a total of 91 elderly patients with IMN,consisting of 51 males(56.0%)and 40 females(44.0%).The median age of the patients was 67 years.The urinary protein creatinine ratio(uPCR)and urinary albumin creatinine ratio(uACR)of the patients were 4 454.3 mg/g and 2 258.5 mg/g,respectively.The median 24-hour urinary protein and urinary albumin levels were 5 098.2 mg/24 h and 2 800.6 mg/24 h,respectively.The average estimated glomerular filtration rate(eGFR)was(60.5±20.4)ml·min-1·1.73 m-2.Out of the total of 61 patients,67.0%achieved remission,including complete and partial remission,within a year of renal biopsy.The levels of uPCR and uACR were significantly higher in the non-remission group compared to the remission group(5 462.5 vs.2 271.1 mg/g,P<0.001;2 774.4 vs.1 320.0 mg/g,P=0.001).Additionally,the levels of 24h urinary protein and urinary albumin were significantly higher in the non-remission group compared to the remission group(6 526.4 vs.3 210.4 mg/g,P=0.002;3 067.7 vs.2 102.4 mg/g,P=0.007).The remission group had a higher proportion of patients receiving immunosuppressive therapy(85.2%vs.33.3%,P<0.001).The remission rates were higher in patients treated with glucocorticoid combined with cyclophosphamide,glucocorticoid combined with calcineurin inhibitors,or glucocorticoid combined with mycophenolate mofetil compared to those receiving conservative treatment(88.2%vs.31.0%,P=0.001;80.0%vs.31.0%,P<0.001;100.0%vs.31.0%,P=0.007).There was no significant difference in remission rate between the three immunosuppressive therapy groups(P>0.05).However,upon further analysis,it was found that the levels of uPCR,uACR,and serum cystatin C(CysC)were higher in the immunosuppressive therapy groups compared to conservative treatment.Additionally,serum total protein and albumin were lower in the immunosuppressive therapy groups,and these differences were statistically significant(P<0.05).Conclusions The majority of elderly patients diagnosed with IMN have multiple comorbidities.For those at high risk with elevated urinary protein levels,early initiation of immunosuppressive therapy may lead to a higher initial urinary protein remission rate.Therefore,it is advisable to develop individualized treatment plans for elderly patients with IMN based on their clinical characteristics,as well as the risks and benefits associated with immunosuppressive therapy.

NephrosisNephrotic syndromeIdiopathic membranous nephropathyImmunosuppressive therapy

梁锦秀、夏方肖、郝文科、胡文学、吴燕华、余枫、赵志、刘伟

展开 >

南方医科大学附属广东省人民医院老年肾病科广东省医学科学院广东省老年医学研究所,广州 510080

南方医科大学第二临床医学院,广州 510515

肾病 肾病综合征 特发性膜性肾病 免疫抑制治疗

广东省人民医院国家自然科学基金启动经费项目广东省人民医院国家自然科学基金启动经费项目广东省自然科学基金自由申请项目

821705229281970525582018A0303130251

2024

中华老年医学杂志
中华医学会

中华老年医学杂志

CSTPCD北大核心
影响因子:1.606
ISSN:0254-9026
年,卷(期):2024.43(2)
  • 15